Recently, multiple ranitidine and Zantac manufacturers recalled their products due to concerns that they contain high levels of NDMA, a likely carcinogen.
On April 1, 2020, the FDA requested that all Ranitidine (Zantac) products be removed from the market.
If you or a loved one were diagnosed with bladder, colon, kidney, rectal, stomach, and another cancer after taking Zantac, contact the Zantac Recall Lawsuit Lawyers today for a free case review.
Zantac (ranitidine), the popular over-the-counter heartburn medication, has recently been at the center of several newly filed lawsuits because of concerns about contamination with a cancer-causing chemical. Recently, two class-action lawsuits were filed against Zantac manufacturer Sanofi-Aventis LLC and Boehringer Ingelheim Pharmaceuticals, who previously held rights to Zantac, with plaintiffs claiming that the companies knowingly put patient health at risk.
Zantac, the most popular brand of ranitidine, is used to help reduce stomach acid. The medication is commonly prescribed to treat ulcers, gastroesophageal reflux disease (GERD), chronic indigestion, and Zollinger-Ellison syndrome. It comes in both over-the-counter and prescription strengths that may be taken by mouth or administered via injection into a muscle or vein.
Ranitidine belongs to a class of drugs known as H2 blockers that work by reducing the amount of acid the stomach produces. H2 receptors are present on the cells in the stomach lining. A histamine chemical normally stimulates these receptors to produce acid to the body help digest food. Ranitidine blocks these receptors, and prevents histamine from producing its normal effect, which causes the stomach to produce less acid.
N-nitrosodimethylamine (NDMA) is a probable carcinogen. It is an industrial waste product, yellowish in appearance with a faint, distinctive odor. Found in cured meats and tobacco smoke, it is a common environmental contaminant. This substance has also been used as a stabilizer in industrial lubricants as well as an ingredient in rocket and jet fuel.
NDMA may also be formed as a by-product of other manufacturing processes. According to the Centers for Disease Control and Prevention (CDC), humans can be exposed to NDMA through a wide variety of sources, including:
NDMA can even form in the stomach during digestion of alkylamine-containing foods and has been detected in small amounts in breast milk. In addition to WHO and IARC, NDMA has been classified by the Environmental Protection Agency (EPA) as probably carcinogenic to humans, because it can modify DNA. Studies have shown the chemical to increase cancer risk in animal experiments.
According to a toxicology review from the World Health Organization, NDMA induces cancer through a process known as biotransformation, interacting with a certain enzyme in the liver. This causes DNA mutation, which is known to be a precursor to the formation of malignant tumors.
As of October 2019, neither the FDA or drug manufacturers had received any adverse event reports associated with NDMA in ranitidine. A class action lawsuit filed in San Francisco in September claims that defendants Sanofi and Boehringer Ingelheim were aware of the danger and failed to warn patients. More recently, a Zantac lawsuit was filed in Florida by a plaintiff who claims his prostate cancer was the result of taking Zantac over a seven-year period.
Types of injuries associated with Zantac and generic forms of ranitidine may include:
Some plaintiffs have already filed lawsuits against the makers of Zantac and of generic ranitidine, and more are expected to be filed in the future. In September 2019, for example, five plaintiffs joined together to file a class-action lawsuit against Zantac manufacturer Sanoti-Aventis LLC and former owner of the rights to Zantac, Boehringer Ingelheim, which manufactured and distributed the drug between October 2006 and January 2017.
The plaintiffs claimed that the defendants failed to warn healthcare providers and the public about the dangers of taking Zantac, and did not reveal that Zantac could produce NDMA in the human body.
If you or a loved one took Zantac or generic ranitidine and suffered a serious cancer injury, you may be eligible to file a Zantac lawsuit to recover damages. Shamis & Gentile, P.A. is now investigating these cases and invites you to call today at 305-479-2299 or fill out a form here and our team of Zantac Recall Lawsuit Lawyers will review your information and will be in contact.